Provided by Tiger Trade Technology Pte. Ltd.

AKESO

102.000
+0.1000.10%
Volume:5.57M
Turnover:571.59M
Market Cap:93.94B
PE:-71.15
High:104.500
Open:101.400
Low:101.100
Close:101.900
52wk High:179.000
52wk Low:80.200
Shares:921.00M
HK Float Shares:921.00M
Volume Ratio:0.81
T/O Rate:0.61%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.434
ROE:-14.53%
ROA:-4.32%
PB:8.93
PE(LYR):-71.15
PS:26.43

Loading ...

Movement Alert|AKESO Falls 3.11% in Regular Trading, Profit-Taking After Two-Day Rally Amid Sector Pullback

Market Focus
·
Jul 24

Movement Alert|AKESO Rises 4.15% in Regular Trading, Ivonescimab Global Phase III OS Data Continues to Improve with New Renal Cancer Collaboration

Market Focus
·
Jul 23

How Akeso’s IO 2.0 Bispecific Push At Akeso (SEHK:9926) Has Changed Its Investment Story

Simply Wall St.
·
Jul 23

Movement Alert|Akeso Rises 4.39% in Regular Trading, Novel Bispecific ADC Completes First Patient Dosing in Phase II NSCLC Study

Market Focus
·
Jul 22

Movement Alert|Akeso Bio Falls 3.05% in Regular Trading, Trading at HK$90.5

Market Focus
·
Jul 21

Akeso Says Press Release Available on Phase II Dosing of Ak146d1 with Ivonescimab in Advanced NSCLC

Reuters
·
Jul 20

Akeso Doses First Patient in Phase Ii Study of Novel Trop2/nectin-4 Bispecific ADC (ak146d1) in Combination with Ivonescimab for Advanced Nsclc

THOMSON REUTERS
·
Jul 20

HK Movers | Biomedical Stocks Rally; REMEGEN, WUXI XDC and KEYMED BIO-B Surge Over 8%

Tiger Newspress
·
Jul 20

Movement Alert|Akeso Rises 3.17% in Regular Trading, Biotech Sector Rallies Broadly with Multiple Buy Ratings Reaffirmed

Market Focus
·
Jul 20

Movement Alert|Akeso Bio Falls 3.63% in Regular Trading, Trading at 93.0 HKD

Market Focus
·
Jul 17

Innovative Drug Stocks Surge Following Inclusion in National Essential Medicines List, Accelerating Grassroots Access

Stock News
·
Jul 15

Movement Alert|Akeso Rises 3.86% in Regular Trading, Partners with Top US Cancer Center to Advance Cadonilimab International Clinical Trials

Market Focus
·
Jul 15

Akeso Launches US Phase II Trial of Cadonilimab Combination in Perioperative Gastric Cancer

Reuters
·
Jul 14

Phase Ii Trial of Cadonilimab(pd-1/ctla-4) Combination Regimen Launches in the United States for Perioperative Treatment of Gastric Cancer

THOMSON REUTERS
·
Jul 14

Movement Alert|Akeso Falls 3.08% in Regular Trading, Trading at 94.25 HKD

Market Focus
·
Jul 13

Movement Alert|Akeso Bio Rises 4.38% in Regular Trading, Innovative Drug Payment Reform Continues to Catalyze Amid Sector-Wide Strength

Market Focus
·
Jul 10

Movement Alert|Akeso Rises 3.32% in Regular Trading, Innovative Drug Payment Reform Continues to Catalyze Alongside Sector Strength

Market Focus
·
Jul 09

Movement Alert|Akeso Rises 3.12% in Regular Trading, Innovative Drug Payment Reform Catalysts Continue After Prior Session Pullback

Market Focus
·
Jul 08

Movement Alert|Akeso Bio Falls 3.24% in Regular Trading, Biotech Sector Broadly Retreats After Recent Rally

Market Focus
·
Jul 07

Movement Alert|Akeso Rises 3.32% in Regular Trading, Innovative Drug Payment Reform Continues to Catalyze Amid Sector-Wide Strength

Market Focus
·
Jul 06